Company profilePharmaceutical#244 of 1,318 in Pakistan✓ No DRAP alerts

ICI Pharmaceuticals Ltd

Pharmaceutical company · 76 brands · 116 molecules

Ranked #25 of 70 companies in Cardiac Care

76 registered products 34 pharmaceutical brands 116 distinct molecules 0 DRAP alerts

Company overview

76
registered products
34
pharmaceutical brands
116
distinct molecules
12
therapeutic classes
0
DRAP alerts

ICI Pharmaceuticals Ltd is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 76 product registrations across 116 distinct molecules. Its portfolio is concentrated in Cardiac Care and Anti-Infectives. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by ICI

64 products matched in our catalogue — each with its observed price and DRAP approved ceiling.

Price ceiling age

DRAP sets a maximum price per registration and revises it only on application. In a market with high inflation, an old ceiling erodes margin in real terms.

18
ceilings with an approval date
0
not revised in 2+ years
2025
oldest approval year
20252
202616

Top molecules by brand count

Folic Acid4 brands
Vildagliptin4 brands
Atenolol3 brands
Naproxen3 brands
Lisinopril3 brands
Amlodipine3 brands
Calcium2 brands

Therapeutic classes

Cardiac Care · 5Anti-Infectives · 5Gastro · 4Antiinflammatory And Antirheumatic Products · 4Other Beta-Lactam, Cephalosporins & Penems · 4Pain Management · 3Cancer · 3Blood Glucose Lowering Drugs, Excluding Insulin · 3Beta Blocking Agent · 2Beta-Lactam Antibacterials, Penicillins · 2Calcium Channel Blockers · 2Psycholeptics; Antipsychotics, Anxiolytics, Hypnotics And Sedatives · 2

Conditions treated

Hypertension · 4Pain Killers · 3Oncology · 3General Infections · 3Ulcer/Reflux/Flatulence/Acidity · 2Oral Agents · 2Probiotic · 1Fungal Infection · 1Schizophrenia/Psychosis · 1Worms/Scabies/Amoebiasis · 1Hormonal Therapy · 1High Cholestrol · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official36 products · Rs 67.5 – Rs 9,411.98
DVAGO47 products · Rs 42.28 – Rs 27,452.19
Servaid44 products · Rs 51.59 – Rs 13,620
Median across source: Rs 267.12

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

Wilshire Laboratories (Private) Limited holds 120 molecules not in this portfolio
AcyclovirAcyclovir SodiumAlfacalcidolAmlodipineAmoxycillinAmoxycillin Base
GETZ PHARMA PAKISTAN (PVT) LTD. holds 255 molecules not in this portfolio
),Formoterol3 ) 20Mg} Folic AcidAcetazolamideAcyclovirAdrenalineAlbendazole
ZAFA PHARMACEUTICAL LABORATORIES (PVT) LTD. holds 145 molecules not in this portfolio
AlbuterolAmikacinAminophyllineAmlodipineAmlodipine BaseAmmonium Chloride

Get the full profile for ICI

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.